Citi Reiterates a 'Buy' on Teva Pharmaceutical (TEVA); Generic Yaz Launch Adds Upside Pressure to Earnings
TEVA Hot Sheet
Rating Summary:9 Buy, 9 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 8 | New: 20
Citi reiterates a 'Buy' on Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), price target $72.
Citi analyst says, "Generic Yaz Could Account for $0.16 in EPS for Teva in 2010E — We assume that Teva reaches a peak market share of 75% of the Yaz market by 4Q10, with Teva pricing Gianvi at a 25%-35% discount to Bayer’s attractive wholesaler acquisition cost of $64.91 per Yaz (24/4) 28 day pack. We assume Teva enjoys 180 days of exclusivity, with no competition from any other generic manufacturer, especially since neither WPI nor NVS’ Sandoz division have received tentative approval from the FDA and are still in litigation with Bayer (NYSE: BAY). We don’t expect that Watson (NYSE: WPI) or Sandoz launch generic Yaz in 2010."
To see all the upgrades/downgrades on shares of TEVA, visit our Analyst Ratings page.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories.
Citi analyst says, "Generic Yaz Could Account for $0.16 in EPS for Teva in 2010E — We assume that Teva reaches a peak market share of 75% of the Yaz market by 4Q10, with Teva pricing Gianvi at a 25%-35% discount to Bayer’s attractive wholesaler acquisition cost of $64.91 per Yaz (24/4) 28 day pack. We assume Teva enjoys 180 days of exclusivity, with no competition from any other generic manufacturer, especially since neither WPI nor NVS’ Sandoz division have received tentative approval from the FDA and are still in litigation with Bayer (NYSE: BAY). We don’t expect that Watson (NYSE: WPI) or Sandoz launch generic Yaz in 2010."
To see all the upgrades/downgrades on shares of TEVA, visit our Analyst Ratings page.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories.
You May Also Be Interested In
- UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
- UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
